Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Goodwill (2018 - 2025)

Akebia Therapeutics (AKBA) has disclosed Goodwill for 7 consecutive years, with $59.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Goodwill changed 0.07% to $59.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $59.0 million, a 0.07% change, with the full-year FY2025 number at $59.0 million, changed 0.07% from a year prior.
  • Goodwill was $59.0 million for Q4 2025 at Akebia Therapeutics, roughly flat from $59.0 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $59.0 million in Q1 2022 to a low of $55.1 million in Q4 2021.
  • A 5-year average of $58.6 million and a median of $59.0 million in 2022 define the central range for Goodwill.
  • Peak YoY movement for Goodwill: grew 7.16% in 2022, then dropped 0.07% in 2024.
  • Akebia Therapeutics' Goodwill stood at $55.1 million in 2021, then rose by 7.16% to $59.0 million in 2022, then changed by 0.0% to $59.0 million in 2023, then decreased by 0.07% to $59.0 million in 2024, then grew by 0.07% to $59.0 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Goodwill are $59.0 million (Q4 2025), $59.0 million (Q3 2025), and $59.0 million (Q2 2025).